Back to Search Start Over

Surveillance of Clinically Complete Responders Using Serial 18 F-FDG PET/CT Scans in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy.

Authors :
Valkema MJ
van der Wilk BJ
Eyck BM
Wijnhoven BPL
Spaander MCW
Doukas M
Lagarde SM
Schreurs WMJ
Roef MJ
van Lanschot JJB
Valkema R
Source :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2021 Apr; Vol. 62 (4), pp. 486-492. Date of Electronic Publication: 2020 Sep 04.
Publication Year :
2021

Abstract

Active surveillance for patients with esophageal cancer and a clinically complete response (cCR) after neoadjuvant chemoradiotherapy (nCRT) is being studied. Active surveillance requires accurate clinical response evaluations. <superscript>18</superscript> F-FDG PET/CT might be able to detect local tumor recurrence after nCRT as soon as the esophagus recovers from radiation-induced esophagitis. The aims of this study were to assess the value of serial <superscript>18</superscript> F-FDG PET/CT scans for detecting local recurrence in patients beyond 3 mo after nCRT and to determine when radiation-induced esophagitis has resolved. Methods: This retrospective multicenter study included patients who had cCR after nCRT, who initially declined surgery, and who subsequently underwent active surveillance. Clinical response evaluations included <superscript>18</superscript> F-FDG PET/CT, endoscopic biopsies, and endoscopic ultrasound with fine-needle aspiration at regular intervals. SUV <subscript>max</subscript> normalized for lean body mass (SUL <subscript>max</subscript> ) was measured at the primary tumor site. The percentage change in SUL <subscript>max</subscript> (Δ%SUL <subscript>max</subscript> ) between the last follow-up scan and the scan at 3 mo after nCRT was calculated. Tumor recurrence was defined as biopsy-proven vital tumor at the initial tumor site. Results: Of 41 eligible patients, 24 patients had recurrent disease at a median of 6.5 mo after nCRT and 17 patients remained cancer free during a median follow-up of 24 mo after nCRT. Five of 24 patients with tumor recurrence had sudden intense SUL <subscript>max</subscript> increases of greater than 180%. In 19 of 24 patients with tumor recurrence, SUL <subscript>max</subscript> gradually increased (median Δ%SUL <subscript>max</subscript> , +18%), whereas SUL <subscript>max</subscript> decreased (median Δ%SUL <subscript>max</subscript> , -12%) in patients with ongoing cCR ( P < 0.001, independent-samples t test). In patients with ongoing cCR, SUL <subscript>max</subscript> was lowest at 11 mo after nCRT. Conclusion: Serial <superscript>18</superscript> F-FDG PET/CT might be a useful tool for detecting tumor recurrence during active surveillance. In patients with ongoing cCR, the lowest SUL <subscript>max</subscript> was reached at 11 mo after nCRT, suggesting that radiation-induced esophagitis had mostly resolved by that time. These findings warrant further evaluation in a larger cohort.<br /> (© 2021 by the Society of Nuclear Medicine and Molecular Imaging.)

Details

Language :
English
ISSN :
1535-5667
Volume :
62
Issue :
4
Database :
MEDLINE
Journal :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Publication Type :
Academic Journal
Accession number :
32887759
Full Text :
https://doi.org/10.2967/jnumed.120.247981